<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551586</url>
  </required_header>
  <id_info>
    <org_study_id>ACH228-004</org_study_id>
    <nct_id>NCT04551586</nct_id>
  </id_info>
  <brief_title>A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1 Study to Assess the Relative Bioavailability of ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, 3-sequence, 3-period crossover study in healthy adult&#xD;
      participants to assess the relative bioavailability of ACH-0145228 when administered as an&#xD;
      immediate release tablet versus powder-in-capsule.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be a 3-sequence, 3-period crossover study in healthy adult participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Bioavailability Of ACH-0145228 Immediate Release Tablet And Powder-In-Capsule</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
    <description>Relative bioavailability will be measured by the ratio of the area under the concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under The Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t) Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Maximum Observed Concentration (Tmax) Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t Of ACH-0145228 Powder-in-capsule Under Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf Of ACH-0145228 Powder-in-capsule Under Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Of ACH-0145228 Powder-in-capsule Under Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax Of ACH-0145228 Powder-in-capsule Under Fasted Conditions</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:&#xD;
Period 1: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).&#xD;
Period 2: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).&#xD;
Period 3: ACH-0145228 as power-in-capsule under fasted conditions (reference).&#xD;
There will be a washout period of at least 5 days between each ACH-0145228 dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:&#xD;
Period 1: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).&#xD;
Period 2: ACH-0145228 as power-in-capsule under fasted conditions (reference).&#xD;
Period 3: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).&#xD;
There will be a washout period of at least 5 days between each ACH-0145228 dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:&#xD;
Period 1: ACH-0145228 as power-in-capsule under fasted conditions (reference).&#xD;
Period 2: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).&#xD;
Period 3: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).&#xD;
There will be a washout period of at least 5 days between each ACH-0145228 dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0145228: Immediate Release</intervention_name>
    <description>ACH-0145228 (240 milligrams) will be administered orally on Day 1.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <other_name>ALXN2050</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0145228: Powder-in-capsule</intervention_name>
    <description>ACH-0145228 (240 milligrams) will be administered orally on Day 1.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <other_name>ALXN2050</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at screening.&#xD;
&#xD;
          2. No clinically significant history or presence of electrocardiogram findings at&#xD;
             screening.&#xD;
&#xD;
          3. Non-sterile male participants must agree to abstinence or use a highly effective&#xD;
             method of contraception.&#xD;
&#xD;
          4. Female participants must be of non-childbearing potential and need not employ a method&#xD;
             of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant laboratory abnormalities.&#xD;
&#xD;
          2. History of any medical or psychiatric condition or disease that might limit the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          3. History or presence of drug or alcohol abuse within previous 2 years, current tobacco&#xD;
             user, and positive drugs-of-abuse screen and alcohol screen at screening or Day -1 of&#xD;
             Period 1.&#xD;
&#xD;
          4. History or presence of clinically significant seizures, head injury, or head trauma.&#xD;
&#xD;
          5. History of procedures that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          6. History of meningococcal infection, or a first-degree relative with a history of&#xD;
             meningococcal infection.&#xD;
&#xD;
          7. A history of significant multiple and/or severe allergies or has had an anaphylactic&#xD;
             reaction or significant intolerability to prescription or non-prescription drugs.&#xD;
&#xD;
          8. Body temperature ≥ 38.0°Celsius at screening or prior to first dosing in Period 1 or&#xD;
             history of febrile illness, or other evidence of infection, within 14 days prior to&#xD;
             (first) dosing.&#xD;
&#xD;
          9. Is a female of childbearing potential.&#xD;
&#xD;
         10. Donation of whole blood from 3 months prior to first dosing, or of plasma from 30 days&#xD;
             before first dosing, and receipt of blood products within 6 months prior to first&#xD;
             dosing.&#xD;
&#xD;
         11. Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives (if known) or 30 days before&#xD;
             first dosing, whichever is longer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Complement</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Tablet</keyword>
  <keyword>Capsule</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

